

Newport Beach and Birch Street

Clinical Research Treatment Trial Flowchart



AML NEWLY DIAGNOSED: NON-INTENSIVE

UCI 21-216

Giltertinib+Venetoclax+Azacitidine in patients w/ FLT3 mutant AML not eligible for intensive induction chemotherapy

FLT3 mutation

Mechanism: FLT3 inhibitor

PI: Jeyakumar

Coord: S. Osorio

Accrual: 2/5

CLL NEWLY DIAGNOSED: HIGH RISK

SWOG S1925

Venetoclax+Obnutumab early intervention vs. delayed therapy in asymptomatic high-risk CLL/SLL

Mechanism: BCL2 inhibitor +anti-CD20 monoclonal antibody

PI: Coombs

Coord: K. McAbee

Accrual: 5/10



GASTRIC/GEJ: NEOADJUVANT

UCI 21-191

(SOC therapy with ctDNA testing)

PI: Dayyani
Coord: A. Luna
Accrual: 12/20

NON-TREATMENT/BASIC SCIENCE

UCI 18-136

PI: Parajuli
Coord: B. Sanchez
Accrual: 82/100

UCI 17-05 (BRCA1 -/+)

PI: Parajuli
Coord: TBD
Accrual: 49/75

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended



 Open to Accrual  Low Accruing  Pending Activation/Suspended

1L METASTATIC

2L METASTATIC

3L METASTATIC

ETCTN 10546 (TNBC)

Cytidine deaminase (CDA) inhibitor + nucleoside hypomethylating agent (HMA)

PI: Parajuli; Coord: R. Kang

Accrual: 2/5



PANCREATIC: BORDERLINE/LOCALLY ADVANCED

ETCTN 10366

M3814 (Peposertib) + radiation therapy

PI: Dayyani
 Coord: S. Duong
 Accrual: 12/18

HCC: 1-3L

UCI 22-106

STAT3 ± Pembrolizumab or ± Atezolizumab and Bevacizumab

PI: Dayyani
 Coord: H. Nguyen
 Accrual: 10/15



MELANOMA: NON-TREATMENT

UCI 19-135

DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)

PI: Yamamoto
Coord: A. Reipolska
Accrual: 105/110



CLDN18.2

UCI 21-10

Bispecific antibody (anti-CLDN18.2 + anti-4-1BB)

PI: Dayyani

Coord: M. Nguyen

Accrual: 34/50